search
Back to results

Innovation in Mammography: Tomosynthesis Pathways (IMPETO)

Primary Purpose

Breast Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Tomosynthesis
2D mammography
Sponsored by
Cancer Prevention and Research Institute, Italy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Breast Cancer focused on measuring breast cancer screening, tomosynthesis, digital mammography

Eligibility Criteria

45 Years - 46 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • 45-46 years old women resident in the screening area

Exclusion Criteria:

  • previous breast cancer
  • written refusal to participate in the screening programme
  • pregnancy, breastfeeding
  • presence of prostheses;
  • ongoing chemotherapy;
  • impossibility to submit the informed consent for linguistic problems or for inability of women to provide informed consent;
  • verified presence of BRCA1 - BRCA2 (Breast Related Cancer Antigens 1 - Breast Related Cancer Antigens 2) genetic mutation or involvement in surveillance path for heredo-familial tumor;
  • previous known tomosynthesis.

Sites / Locations

  • South-Est Local Health Unit
  • Oncological Network, Prevention and Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

2D mammography

Tomosynthesis

Arm Description

45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.

45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.

Outcomes

Primary Outcome Measures

the cumulative incidence of advanced screen-detected cancers (T2 +) and the cumulative incidence of advanced interval cancers (T2 +)
number of T2+ screen-detected cancers divided by all screened women at subsequent round of screening and number of T2+ interval cancers divided by all screened women at subsequent round of screening.

Secondary Outcome Measures

recall rate
number of women recalled to perform 2nd level assessments) for invasive tests and for non-invasive examinations in the two arms divided by the number of screened women
detection rate
number of breast cancer cases (invasive and in situ forms) divided by the number of screened women (per 1,000)
benign biopsies rate
number of benign biopsies divided by the total number of biopsies
cost analysis
an activity based cost analysis will be performed in order to obtain the real costs of DBT screening pathway.

Full Information

First Posted
June 27, 2018
Last Updated
July 13, 2018
Sponsor
Cancer Prevention and Research Institute, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT03587259
Brief Title
Innovation in Mammography: Tomosynthesis Pathways
Acronym
IMPETO
Official Title
Innovation in Mammography: Tomosynthesis Pathways
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
September 3, 2018 (Anticipated)
Primary Completion Date
September 1, 2020 (Anticipated)
Study Completion Date
September 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cancer Prevention and Research Institute, Italy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study aims at evaluating the introduction of tomosynthesis in mammography screening, analyzing the benefits, disadvantages and feasibility in current clinical practice. It involves women aged 45-46 that will be divided, by drawing lots, into two groups: one group will do the 2D digital mammography (control group), while the other group (intervention group) will do tomosynthesis. In the intervention group the 2D two-dimensional mammography will be reconstructed starting from tomosynthesis without exposing women to other radiation.
Detailed Description
The IMPETO trial is a population-based, multicentre, randomised trial aimed at evaluating the clinical accuracy of Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM) compared to standard two-dimensional digital mammography alone (2D) in a screening programme. 45-46 year-old women resident in the screening centre catchment area of Florence and South-Est Local Health Unit are invited to attend for mammography screening and asked for informed consent to be included in the study. Women are then randomly allocated either to an usual care group (2D mammography) or to the intervention group. In the intervention group, DBT combined with sDM is proposed in order to reduce radiation exposure. The next year women of both groups will be invited to attend the usual screening examination (2D mammography). The enrolment will last 12-18 months; the whole study 36 months. The estimated sample size is 6000 women, 3000 per arm. Data will be pooled with the trial "Screening for Breast Cancer With Digital Breast Tomosynthesis", ClinicalTrials.gov Identifier: NCT02698202.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
breast cancer screening, tomosynthesis, digital mammography

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
6000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
2D mammography
Arm Type
Active Comparator
Arm Description
45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
Arm Title
Tomosynthesis
Arm Type
Experimental
Arm Description
45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
Intervention Type
Diagnostic Test
Intervention Name(s)
Tomosynthesis
Other Intervention Name(s)
Digital Breast Tomosynthesis (DBT)
Intervention Description
DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
Intervention Type
Diagnostic Test
Intervention Name(s)
2D mammography
Intervention Description
2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
Primary Outcome Measure Information:
Title
the cumulative incidence of advanced screen-detected cancers (T2 +) and the cumulative incidence of advanced interval cancers (T2 +)
Description
number of T2+ screen-detected cancers divided by all screened women at subsequent round of screening and number of T2+ interval cancers divided by all screened women at subsequent round of screening.
Time Frame
three years
Secondary Outcome Measure Information:
Title
recall rate
Description
number of women recalled to perform 2nd level assessments) for invasive tests and for non-invasive examinations in the two arms divided by the number of screened women
Time Frame
two years
Title
detection rate
Description
number of breast cancer cases (invasive and in situ forms) divided by the number of screened women (per 1,000)
Time Frame
two years
Title
benign biopsies rate
Description
number of benign biopsies divided by the total number of biopsies
Time Frame
two years
Title
cost analysis
Description
an activity based cost analysis will be performed in order to obtain the real costs of DBT screening pathway.
Time Frame
two years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
46 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 45-46 years old women resident in the screening area Exclusion Criteria: previous breast cancer written refusal to participate in the screening programme pregnancy, breastfeeding presence of prostheses; ongoing chemotherapy; impossibility to submit the informed consent for linguistic problems or for inability of women to provide informed consent; verified presence of BRCA1 - BRCA2 (Breast Related Cancer Antigens 1 - Breast Related Cancer Antigens 2) genetic mutation or involvement in surveillance path for heredo-familial tumor; previous known tomosynthesis.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paola Mantellini, MDr
Phone
05532697961
Email
p.mantellini@ispro.toscana.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paola Mantellini, MDr
Organizational Affiliation
Oncological Network, Prevention and Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
South-Est Local Health Unit
City
Arezzo
ZIP/Postal Code
52100
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberto Turillazzi, MDr
Email
roberto.turillazzi@uslsudest.toscana.it
Facility Name
Oncological Network, Prevention and Research Institute
City
Florence
ZIP/Postal Code
50139
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paola Mantellini, MDr

12. IPD Sharing Statement

Citations:
PubMed Identifier
23623721
Citation
Ciatto S, Houssami N, Bernardi D, Caumo F, Pellegrini M, Brunelli S, Tuttobene P, Bricolo P, Fanto C, Valentini M, Montemezzi S, Macaskill P. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013 Jun;14(7):583-9. doi: 10.1016/S1470-2045(13)70134-7. Epub 2013 Apr 25.
Results Reference
background
PubMed Identifier
23297332
Citation
Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, Izadi M, Jebsen IN, Jahr G, Krager M, Niklason LT, Hofvind S, Gur D. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 2013 Apr;267(1):47-56. doi: 10.1148/radiol.12121373. Epub 2013 Jan 7.
Results Reference
background
PubMed Identifier
25599513
Citation
Gilbert FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Lim YY, Purushothaman H, Strudley C, Astley SM, Morrish O, Young KC, Duffy SW. The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme--a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess. 2015 Jan;19(4):i-xxv, 1-136. doi: 10.3310/hta19040.
Results Reference
background
PubMed Identifier
24484063
Citation
Skaane P, Bandos AI, Eben EB, Jebsen IN, Krager M, Haakenaasen U, Ekseth U, Izadi M, Hofvind S, Gullien R. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014 Jun;271(3):655-63. doi: 10.1148/radiol.13131391. Epub 2014 Jan 24.
Results Reference
background
PubMed Identifier
24293498
Citation
Paci E, Mantellini P, Giorgi Rossi P, Falini P, Puliti D; TBST Working Group. [Tailored Breast Screening Trial (TBST)]. Epidemiol Prev. 2013 Jul-Oct;37(4-5):317-27. Italian.
Results Reference
background
PubMed Identifier
26496565
Citation
McDonald ES, McCarthy AM, Akhtar AL, Synnestvedt MB, Schnall M, Conant EF. Baseline Screening Mammography: Performance of Full-Field Digital Mammography Versus Digital Breast Tomosynthesis. AJR Am J Roentgenol. 2015 Nov;205(5):1143-8. doi: 10.2214/AJR.15.14406.
Results Reference
background
PubMed Identifier
23175484
Citation
Bernardi D, Ciatto S, Pellegrini M, Anesi V, Burlon S, Cauli E, Depaoli M, Larentis L, Malesani V, Targa L, Baldo P, Houssami N. Application of breast tomosynthesis in screening: incremental effect on mammography acquisition and reading time. Br J Radiol. 2012 Dec;85(1020):e1174-8. doi: 10.1259/bjr/19385909.
Results Reference
background
PubMed Identifier
28540564
Citation
Bernardi D, Belli P, Benelli E, Brancato B, Bucchi L, Calabrese M, Carbonaro LA, Caumo F, Cavallo-Marincola B, Clauser P, Fedato C, Frigerio A, Galli V, Giordano L, Giorgi Rossi P, Golinelli P, Morrone D, Mariscotti G, Martincich L, Montemezzi S, Naldoni C, Paduos A, Panizza P, Pediconi F, Querci F, Rizzo A, Saguatti G, Tagliafico A, Trimboli RM, Zappa M, Zuiani C, Sardanelli F. Digital breast tomosynthesis (DBT): recommendations from the Italian College of Breast Radiologists (ICBR) by the Italian Society of Medical Radiology (SIRM) and the Italian Group for Mammography Screening (GISMa). Radiol Med. 2017 Oct;122(10):723-730. doi: 10.1007/s11547-017-0769-z. Epub 2017 May 25.
Results Reference
background
PubMed Identifier
25929946
Citation
Lang K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S. Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmo Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol. 2016 Jan;26(1):184-90. doi: 10.1007/s00330-015-3803-3. Epub 2015 May 1.
Results Reference
background
PubMed Identifier
26943342
Citation
Lang K, Nergarden M, Andersson I, Rosso A, Zackrisson S. False positives in breast cancer screening with one-view breast tomosynthesis: An analysis of findings leading to recall, work-up and biopsy rates in the Malmo Breast Tomosynthesis Screening Trial. Eur Radiol. 2016 Nov;26(11):3899-3907. doi: 10.1007/s00330-016-4265-y. Epub 2016 Mar 4.
Results Reference
background

Learn more about this trial

Innovation in Mammography: Tomosynthesis Pathways

We'll reach out to this number within 24 hrs